Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target

Benzinga Newsdesk www.benzinga.com Positive 75.3%

Neg 0% Neu 0% Pos 75.3%

Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.